KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities (2016 - 2025)

Acadia Pharmaceuticals has reported Total Non-Current Liabilities over the past 15 years, most recently at $317.7 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $317.7 million for Q4 2025, down 27.29% from a year ago — trailing twelve months through Dec 2025 was $317.7 million (down 27.29% YoY), and the annual figure for FY2025 was $317.7 million, down 27.29%.
  • Total Non-Current Liabilities for Q4 2025 was $317.7 million at Acadia Pharmaceuticals, down from $399.6 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ACAD hit a ceiling of $436.9 million in Q4 2024 and a floor of $145.9 million in Q3 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $266.7 million (2023), compared with a mean of $270.9 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 69.38% in 2023 and later dropped 27.29% in 2025.
  • Acadia Pharmaceuticals' Total Non-Current Liabilities stood at $152.2 million in 2021, then increased by 17.17% to $178.3 million in 2022, then surged by 69.38% to $302.1 million in 2023, then skyrocketed by 44.65% to $436.9 million in 2024, then dropped by 27.29% to $317.7 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $317.7 million (Q4 2025), $399.6 million (Q3 2025), and $374.6 million (Q2 2025) per Business Quant data.